AI-powered search

What Treatment Is Most Effective for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria?

Most efficacious treatment achieved with ligelizumab 72 or 240 mg and omalizumab 300 or 600 mg for chronic spontaneous urticaria

By Dermsquared Editorial Team | September 01, 2021

The researchers found that the standardized mean differences for change in urticaria symptoms were –1.05, –1.07, –0.77, and –0.59 for ligelizumab 72 and 240 mg and omalizumab 300 and 600 mg, respectively. There were no significant differences observed in treatment unacceptability. Based on network estimates, the most efficacious treatments with respect to benefits and harms were achieved with ligelizumab 72 or 240 mg (large beneficial effect) and omalizumab 300 or 600 mg (moderate beneficial effect).

"Head-to-head trials with high methodologic quality and harmonized design and outcome definitions are needed to help inform subsequent international guidelines for the management of CSU," the authors write.

Abstract/Full Text (subscription or payment may be required)


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved